Sugar-free, zero-glycemic sweetening with calorie label exclusion
Sukré® provides sweetness at ~70% of sucrose intensity with only 0.4 kcal/g caloric contribution — and per FDA guidance, allulose can be excluded from total and added sugar labeling. This dual advantage (functional sweetness + label-friendly status) makes Sukré® uniquely valuable for clean-label products targeting sugar reduction without resorting to artificial sweeteners or high-intensity sweetener blends.
Blood glucose and insulin reduction
Multiple clinical RCTs confirm allulose reduces postprandial blood glucose and insulin response when consumed with carbohydrate meals — inhibiting intestinal alpha-glucosidase enzymes (similar to acarbose, a diabetes medication) to slow glucose absorption. This glucose-lowering mechanism extends allulose beyond sweetening into active metabolic health ingredient territory.
Body fat reduction and anti-obesity effects
A meta-analysis of RCTs confirmed allulose supplementation (7–15g/day) significantly reduced body weight, BMI, waist circumference, and body fat percentage vs. control — effects attributed to alpha-glucosidase inhibition reducing carbohydrate absorption, improved fat oxidation signaling, and gut microbiome modulation including increased Akkermansia muciniphila abundance.
Alpha-glucosidase inhibition and Akkermansia stimulation
Allulose competitively inhibits intestinal brush border alpha-glucosidases (maltase, sucrase) — enzymes that break down complex carbohydrates into glucose for absorption. This mechanism reduces glucose absorption rate and postprandial glycemia, functioning similarly to the pharmaceutical alpha-glucosidase inhibitor acarbose but with substantially better GI tolerance. Unabsorbed allulose reaching the colon selectively promotes Akkermansia muciniphila growth — a keystone mucus-layer bacterium associated with improved metabolic health, insulin sensitivity, and reduced gut permeability.
Meta-analysis of 9 randomized controlled trials examining allulose effects on postprandial blood glucose, insulin, body composition, and metabolic markers.
Adults across 9 RCTs including subjects with and without metabolic syndrome.
Allulose significantly reduced postprandial blood glucose (−0.44 mmol/L), insulin area under the curve, body weight (−0.58 kg), and body fat vs. control. Alpha-glucosidase inhibitory mechanism confirmed. Well-tolerated up to 54g/day. Supports allulose as both a functional sweetener and metabolic health ingredient.